Week 13 onward: 10 mg weekly, with potential increase to 12.5 mg or 15 mg based on response and tolerability
GLP-1 medications work by suppressing a persons appetite and managing their blood sugar levels
Available studies strongly advise against stacking or combining multi-agonist incretin mimetics
Most digestive symptoms are mild to moderate, transient, and can be successfully managed with practical strategies and, where necessary, symptomatic treatment
However, the FDA announced on October 2, 2024, that the tirzepatide shortage has ended, which would begin to impact the availability of compounded tirzepatide
Suitability depends on your medical history, current symptoms, and any medication you are taking